Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist

Journal of Pharmacology and Experimental Therapeutics

Volumn 327, Issue 3, 2008, Pages 736-745

  Iglarz, Marc ^a   Binkert, Christoph ^a   Morrison, Keith ^a   Fischli, Walter ^a   Gatfield, John ^a   Treiber, Alexander ^a   Weller, Thomas ^a   Bolli, Martin H ^a   Boss, Christoph ^a   Buchmann, Stephan ^a   Capeleto, Bruno ^a   Hess, Patrick ^a   Qiu, Changbin ^a   Clozel, Martine ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACT 064992; ACT 132577; ACTELION 1; DRUG METABOLITE; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; MACITENTAN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; AORTA CONSTRICTION; ARTICLE; BINDING ASSAY; CALCIUM MOBILIZATION; CARDIOVASCULAR DISEASE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DIABETES MELLITUS; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; HEART RIGHT VENTRICLE HYPERTROPHY; HUMAN; HUMAN CELL; KIDNEY FAILURE; LUNG PRESSURE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEINURIA; PULMONARY HYPERTENSION; RAT; RECEPTOR AFFINITY; RECEPTOR BLOCKING; SINGLE DRUG DOSE; SURVIVAL RATE; TISSUE SPECIFICITY; TRACHEA;

ANIMALS; AORTA; CALCIUM SIGNALING; CELL LINE; DRUG DELIVERY SYSTEMS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; KIDNEY DISEASES; PYRIMIDINES; RATS; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; RECEPTORS, ENDOTHELIN; SULFONAMIDES; SURVIVAL RATE; TRACHEA; VASOCONSTRICTION;

EID: 57349133022     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.142976     Document Type: Article

References (40)

1. Allen RI, Box KJ, Comer JE, Peake C, and Tam KY (1998) Multiwavelength spectrophotometric determination of acid dissociation constants of ionizable drugs. J Pharm Biomed Anal 17:699-712.
2. Amiri F, Virdis A, Neves MF, Iglarz M, Seidah NG, Touyz RM, Reudelhuber TL, and Schiffrin EL (2004) Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction. Circulation 110:2233-2240.
3. Böhm F, Ahlborg G, Johansson BL, Hansson LO, and Pernow J (2002) Combined endothelin receptor blockade evokes enhanced vasodilatation in patients with atherosclerosis. Arterioscler Thromb Vasc Biol 22:674-679.
4. Breu V, Ertel SI, Roux S, and Clozel M (1998) The pharmacology of bosentan. Expert Opin Investig Drugs 7:1173-1192.
5. Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, Bruns C, Prieschl E, Baumruker T, Hiestand P, et al. (2002) The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 277:21453-21457.
6. Cardillo C, Campia U, Bryant MB, and Panza JA (2002) Increased activity of endogenous endothelin in patients with type II diabetes mellitus. Circulation 106:1783-1787.
7. Cardillo C, Kilcoyne CM, Cannon RO 3rd, and Panza JA (2000) Interactions between nitric oxide and endothelin in the regulation of vascular tone of human resistance vessels in vivo. Hypertension 35:1237-1241.
8. Cardillo C, Kilcoyne CM, Waclawiw M, Cannon RO 3rd, and Panza JA (1999) Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension 33:753-758.
9. Chakrabarti S, Cukiernik M, Hileeto D, Evans T, and Chen S (2000) Role of vasoactive factors in the pathogenesis of early changes in diabetic retinopathy. Diabetes Metab Res Rev 16:393-407.
10. Clozel M and Gray GA (1995) Are there different ETB receptors mediating constriction and relaxation? J Cardiovasc Pharmacol 26 (Suppl 3):S262-S264.
11. Clozel M, Hess P, Rey M, Iglarz M, Binkert C, and Qiu C (2006) Bosentan, sildenafil, and their combination in the monocrotaline model of pulmonary hypertension in rats. Exp Biol Med (Maywood) 231:967-973.
12. Clozel M, Ramuz H, Clozel JP, Breu V, Hess P, Löffler BM, Coassolo P, and Roux S (1999) Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use. J Pharmacol Exp Ther 290:840-846.
13. Cukiernik M, Hileeto D, Evans T, Mukherjee S, Downey D, and Chakrabarti S (2004) Vascular endothelial growth factor in diabetes induced early retinal abnormalities. Diabetes Res Clin Pract 65:197-208.
14. Ding SS, Qiu C, Hess P, Xi JF, Zheng N, and Clozel M (2003) Chronic endothelin receptor blockade prevents both early hyperfiltration and late overt diabetic nephropathy in the rat. J Cardiovasc Pharmacol 42:48-54.
15. Fukui M, Nakamura T, Ebihara I, Osada S, Tomino Y, Masaki T, Goto K, Furuichi Y, and Koide H (1993) Gene expression for endothelins and their receptors in glomeruli of diabetic rats. J Lab Clin Med 122:149-156.
16. Gregan B, Jürgensen J, Papsdorf G, Furkert J, Schaefer M, Beyermann M, Rosenthal W, and Oksche A (2004) Ligand-dependent differences in the internalization of endothelin A and endothelin B receptor heterodimers. J Biol Chem 279:27679-27687.
17. Haug C, Schmid-Kotsas A, Zorn U, Schuett S, Gross HJ, Gruenert A, and Bachem MG (2001) Endothelin-1 synthesis and endothelin B receptor expression in human coronary artery smooth muscle cells and monocyte-derived macrophages is upregulated by low density lipoproteins. J Mol Cell Cardiol 33:1701-1712.
18. Hocher B, Schwarz A, Fagan KA, Thöne-Reineke C, El-Hag K, Kusserow H, Elitok S, Bauer C, Neumayer HH, Rodman DM, et al. (2000) Pulmonary fibrosis and chronic lung inflammation in ET-1 transgenic mice. Am J Respir Cell Mol Biol 23:19-26.
19. Hocher B, Thöne-Reineke C, Rohmeiss P, Schmager F, Slowinski T, Burst V, Siegmund F, Quertermous T, Bauer C, Neumayer HH, et al. (1997) Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest 99:1380-1389.
20. Jasmin JF, Lucas M, Cernacek P, and Dupuis J (2001) Effectiveness of a nonselective ET(A/B) and a selective ET(A) antagonist in rats with monocrotaline-induced pulmonary hypertension. Circulation 103:314-318.
21. Kakoki M, Hirata Y, Hayakawa H, Tojo A, Nagata D, Suzuki E, Kimura K, Goto A, Kikuchi K, Nagano T, et al. (1999) Effects of hypertension, diabetes mellitus, and hypercholesterolemia on endothelin type B receptor-mediated nitric oxide release from rat kidney. Circulation 99:1242-1248.
22. Lee YJ, Shin SJ, and Tsai JH (1994) Increased urinary endothelin-1-like immunoreactivity excretion in NIDDM patients with albuminuria. Diabetes Care 17:263-266.
23. Löffler BM, Breu V, and Clozel M (1993) Effect of different endothelin receptor antagonists and of the novel non-peptide antagonist Ro 46-2005 on endothelin levels in rat plasma. FEBS Lett 333:108-110.
24. Lund W (1994) The Pharmaceutical Codex: Principles and Practice of Pharmaceutics, 12th ed., pp 70-71, The Pharmaceutical Press, London, UK.
25. Masuzawa K, Jesmin S, Maeda S, Zaedi S, Shimojo N, Miyauchi T, and Goto K (2006) Effect of endothelin dual receptor antagonist on VEGF levels in streptozotocininduced diabetic rat retina. Exp Biol Med (Maywood) 231:1090-1094.
26. Mulder P, Boujedaini H, Richard V, Henry JP, Renet S, Münter K, and Thuillez C (2002) Long-term survival and hemodynamics after endothelin-a receptor antagonism and angiotensin-converting enzyme inhibition in rats with chronic heart failure: monotherapy versus combination therapy. Circulation 106:1159-1164.
27. Mulder P, Richard V, Derumeaux G, Hogie M, Henry JP, Lallemand F, Compagnon P, Mace B, Comoy E, Letac B, et al. (1997) Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation 96:1976-1982.
28. Muller DN, Mervaala EM, Schmidt F, Park JK, Dechend R, Genersch E, Breu V, Löffler BM, Ganten D, Schneider W, et al. (2000) Effect of bosentan on NF-kappaB, inflammation, and tissue factor in angiotensin II-induced end-organ damage. Hypertension 36:282-290.
29. Porter KE, Olojugba DH, Masood I, Pemberton M, Bell PR, and London NJ (1998) Endothelin-B receptors mediate intimal hyperplasia in an organ culture of human saphenous vein. J Vasc Surg 28:695-701.
30. Rossi G, Albertin G, Belloni A, Zanin L, Biasolo MA, Prayer-Galetti T, Bader M, Nussdorfer GG, Palù G, and Pessina AC (1994) Gene expression, localization, and characterization of endothelin A and B receptors in the human adrenal cortex. J Clin Invest 94:1226-1234.
31. Sauvageau S, Thorin E, Caron A, and Dupuis J (2007) Endothelin-1-induced pulmonary vasoreactivity is regulated by ET(A) and ET(B) receptor interactions. J Vasc Res 44:375-381.
32. Schrijvers BF, De Vriese AS, and Flyvbjerg A (2004) From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev 25:971-1010.
33. Serneri GG, Cecioni I, Vanni S, Paniccia R, Bandinelli B, Vetere A, Janming X, Bertolozzi I, Boddi M, Lisi GF, et al. (2000) Selective upregulation of cardiac endothelin system in patients with ischemic but not idiopathic dilated cardiomyopathy: endothelin-1 system in the human failing heart. Circ Res 86:377-385.
34. Shi-Wen X, Denton CP, Dashwood MR, Holmes AM, Bou-Gharios G, Pearson JD, Black CM, and Abraham DJ (2001) Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J Invest Dermatol 116:417-425.
35. Teerlink JR, Carteaux JP, Sprecher U, Löffler BM, Clozel M, and Clozel JP (1995) Role of endogenous endothelin in normal hemodynamic status of anesthetized dogs. Am J Physiol 268:H432-H440.
36. Verhaar MC, Strachan FE, Newby DE, Cruden NL, Koomans HA, Rabelink TJ, and Webb DJ (1998) Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 97:752-756.
37. Wagner OF, Christ G, Wojta J, Vierhapper H, Parzer S, Nowotny PJ, Schneider B, Waldhäusl W, and Binder BR (1992) Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem 267:16066-16068.
38. Yang LL, Gros R, Kabir MG, Sadi A, Gotlieb AI, Husain M, and Stewart DJ (2004) Conditional cardiac overexpression of endothelin-1 induces inflammation and dilated cardiomyopathy in mice. Circulation 109:255-261.
39. Yang Z, Krasnici N, and Lüscher TF (1999) Endothelin-1 potentiates human smooth muscle cell growth to PDGF: effects of ETA and ETB receptor blockade. Circulation 100:5-8.
40. Yokomori H, Oda M, Yasogawa Y, Nishi Y, Ogi M, Takahashi M, and Ishii H (2001) Enhanced expression of endothelin B receptor at protein and gene levels in human cirrhotic liver. Am J Pathol 159:1353-1362.